Teva Pharmaceutical Industries: Why Investors Should Buy the Dip
Shares of Teva Pharmaceutical (TEVA) have plunged in price due to the company’s weak financials and its reduction of its top-line guidance. However, can the stock rebound by the company leveraging its broad product and services portfolio? Read on. Let’s find out.
StockNews.com ·